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Abstract
Background: Hypocatabolism of the amyloid b-protein (Ab) by insulin-degrading enzyme (IDE) is implicated in the
pathogenesis of Alzheimer disease (AD), making pharmacological activation of IDE an attractive therapeutic strategy.
However, it has not been established whether the proteolytic activity of IDE can be enhanced by drug-like compounds.
Methodology/Principal Findings: Based on the finding that ATP and other nucleotide polyphosphates modulate IDE
activity at physiological concentrations, we conducted parallel high-throughput screening campaigns in the absence or
presence of ATP and identified two compounds—designated Ia1 and Ia2—that significantly stimulate IDE proteolytic
activity. Both compounds were found to interfere with the crosslinking of a photoaffinity ATP analogue to IDE, suggesting
that they interact with a bona fide ATP-binding domain within IDE. Unexpectedly, we observed highly synergistic activation
effects when the activity of Ia1 or Ia2 was tested in the presence of ATP, a finding that has implications for the mechanisms
underlying ATP-mediated activation of IDE. Notably, Ia1 and Ia2 activated the degradation of Ab by ,700% and ,400%,
respectively, albeit only when Ab was presented in a mixture also containing shorter substrates.
Conclusions/Significance: This study describes the first examples of synthetic small-molecule activators of IDE, showing
that pharmacological activation of this important protease with drug-like compounds is achievable. These novel activators
help to establish the putative ATP-binding domain as a key modulator of IDE proteolytic activity and offer new insights into
the modulatory action of ATP. Several larger lessons abstracted from this screen will help inform the design of future
screening campaigns and facilitate the eventual development of IDE activators with therapeutic utility.
Citation: Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, et al. (2009) Small-Molecule Activators of Insulin-Degrading Enzyme Discovered through
High-Throughput Compound Screening. PLoS ONE 4(4): e5274. doi:10.1371/journal.pone.0005274
Editor: Andreas Hofmann, Griffith University, Australia
Received February 23, 2009; Accepted March 25, 2009; Published April 22, 2009
Copyright:  2009 Cabrol et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Supported by grants from the National Institutes of Health (AG030718 and DA024888 to MAL and AG012749 to DJS and MAL) and by a generous
donation from The Unforgettable Fund (to MAL and CC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation
of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Leissring@mayo.edu
Introduction
Alzheimer disease (AD) is a devastating and increasingly
common neurodegenerative disorder characterized by abnormal
accumulation of the amyloid b-protein (Ab) in brain regions
subserving memory and other cognitive functions [1]. Ab is a
complex mixture of peptides ranging in size from 37 to 43 amino
acids that are cleaved from the amyloid precursor protein by the
successive action of aspartyl proteases known as b- and c-secretase
[2]. A wealth of evidence from human molecular genetics, animal
modeling studies and other fields supports the hypothesis that the
proximal cause of AD is chronic elevations in cerebral Ab, either
all forms or specifically longer species, such as Ab42, which have a
greater propensity to self-assemble into neurotoxic oligomers and
higher-order aggregates, and which predominate in the amyloid
plaques that characterize the disease [3–6].
The latter findings have prompted extensive efforts to develop
therapies aimed at achieving sustained reductions in cerebral Ab,
thereby reducing the formation of neurotoxic Ab oligomers and
plaques. Toward this common goal, several different strategies are
being vigorously pursued, including the approaches of (i) lowering
the production of total Ab with secretase inhibitors, (ii) selectively
lowering Ab42 with c-secretase modulators, (iii) antibody-based
clearance of pre-existing Ab deposits by means of active or passive
immunization, and (iv) reducing the self-assembly of Ab with anti-
aggregation compounds [7]. An alternative approach that has
received less attention is the strategy of increasing the proteolysis of
Ab after it is produced [8]. Accumulating evidence has shown that
cerebral Ab levels are potently regulated by the concerted action
of several different proteases, including neprilysin and insulin-
degrading enzyme (IDE) [8]. Overexpression of either of the latter
proteases in AD mouse models has been shown to retard or even
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5274completely prevent amyloid plaque formation and downstream
cytopathology [9,10].
Notwithstanding the theoretical merits of this approach, the
idea that Ab degradation can be enhanced pharmacologically has
generally been regarded as, at best, a challenging objective.
Despite this widespread perception, this goal has in fact already
been achieved in practice: Jacobsen and colleagues recently
described the development of an inhibitor of plasminogen
activator inhibitor-1, an endogenous inhibitor of the conversion
of plasminogen to plasmin—a known Ab-degrading protease—by
tissue-type and urokinase-type plasminogen activators [11].
Notably, the inhibitor developed by this group was found to
effectively lower brain Ab levels and even to reverse cognitive
defects in an AD mouse model [11].
In the present study, we sought to achieve this same goal, in this
case by identifying compounds that activate or disinhibit IDE, an
atypical zinc-metalloprotease that is strongly linked both function-
ally and genetically to the pathogenesis of AD [8,12–14]. Among
known Ab-degrading proteases, several lines of evidence suggest
that IDE is a particularly attractive target for pharmacological
activation. First and foremost, a substantial body of genetic
evidence implicates variations in and around the Ide gene with the
incidence and onset of AD [15–18], thus strongly supporting a key
role for this protease in disease-relevant functions. Second, several
studies suggest that IDE—a secreted enzyme [19]—is the principal
protease responsible for the degradation of Ab in the extracellular
space [20,21]. Third, IDE possesses distinctive structural features
that appear to render it uniquely amenable to pharmacological
activation [22]. As recent crystal structures have revealed [23–25],
IDE possesses an unusual tertiary structure, consisting of two
bowl-shaped halves connected by a flexible linker. This configu-
ration allows the enzyme to adopt an ‘‘open’’ conformation, that
permits the entry of substrates and exit of products, and a ‘‘closed’’
conformation, wherein substrates are completely entrapped within
an unusually large internal chamber [23]. Enzymologic and
biophysical studies suggest that IDE normally exists in the closed,
inactive conformation, held in place by a ‘‘latch’’ mechanism
comprised of extensive hydrogen bonding between the N- and C-
terminal halves [22,23]. Mutations that disrupt this hydrogen
bonding have been shown to activate the protease by as much as
,40 fold, suggesting that the same effect might be achieved
pharmacologically [22,23]. Finally, multiple studies have suggested
that IDE can be activated by any of several independent means,
including substrate activation [26,27] and cysteine-specific alkyl-
ation [28] through a variety of proposed mechanisms (see
Discussion).
Of special relevance to the present application, IDE activity has
also been shown to be modulated by ATP and other nucleotide
polyphosphates in a manner that is both bidirectional and
substrate-selective [24,29,30]. Camberos and colleagues initially
reported that ATP inhibits IDE-mediated insulin degradation at
physiological concentrations [30]. Remarkably, ATP and related
compounds were later found to dramatically activate the hydrolysis
of shorter substrates by as much as ,70-fold [24,29].
Prompted by the latter findings, here we conducted a high-
throughput screening campaign optimized to detect compounds
that interact with the putative ATP-binding domain within IDE.
We discovered two compounds that activate IDE activity as much
as ,700%. Despite the lack of structural similarities with ATP, the
discovered compounds induced similar enzymologic effects and
competed with the crosslinking of an azido-ATP derivative to IDE,
yet paradoxically were found to act synergistically with ATP in
activating IDE proteolytic activity. We show further that the
discovered compounds can activate the degradation of Ab, albeit
only when presented in a mixture also containing shorter
substrates. Together, our study describes the discovery of the first
drug-like activators of IDE, the characterization of which provides
several new insights into the mechanistic basis for pharmacological
activation of IDE.
Results
Toward the goal of discovering pharmacological activators of
IDE, we planned a compound screening campaign using the
fluorogenic peptide substrate, SP1 (Fig. S1A), as a read-out for
IDE activity. The goal of identifying activators of a protease is
greatly facilitated if its activity is normally regulated by
endogenous inhibitors, for this makes it possible to identify
compounds that disrupt the inhibitor-protease interaction, thereby
disinhibiting—i.e., activating—the protease. Based on a report
showing that insulin degradation by IDE was inhibited by ATP
[30], we therefore planned to conduct parallel screening
campaigns incorporating this putative endogenous inhibitor.
During the assay development phase, we confirmed that ATP
inhibited the degradation of Ab by IDE at physiological
concentrations (Fig. 1A). Unexpectedly, ATP was found to
potently activate the hydrolysis of SP1 (Fig. 1B,C; [31]) and also
a structurally similar fluorogenic peptide substrate, FRET1
(Fig. 1D; Fig. S1B; [28]), a result that was confirmed by
subsequent reports [24,29]. Based on these results, we conducted
parallel compound screening campaigns in the presence or
absence of a near-maximal activating concentration of ATP
(1 mM; see Materials and Methods). By comparing the effects of
compounds under these contrasting conditions (Fig. 1E), several
categories of compounds could in principle be identified, including
compounds that mimic ATP (Fig. 1E,i), compounds that activate
IDE independently of ATP (Fig. 1E,ii), compounds that act
synergistically with ATP (Fig. 1E,iii), and compounds that disrupt
the activation effect induced by ATP (Fig. 1E,iv).
The primary screening campaign was conducted robotically in
384-well format using a library of ,32,000 compounds comprised
of 704 FDA-approved compounds, 352 natural products, a
tetrapeptide library consisting of all possible permutations of 8
amino acids (Glu, His, Lys, Pro, Gln, Val, Trp, Tyr), and an
additional 27,300 small-molecule pharmacophores conforming to
Lipinski’s rules [32]. Compounds showing activation .150% in
the absence or presence of ATP were cherry-picked, spotted on
384-well plates and rescreened robotically. For compounds
showing reproducible activation, dose-response curves were
subsequently determined manually using both SP1 and FRET1,
and for this phase, the fluorescence read-out was monitored
continuously throughout the reaction period to identify com-
pounds exhibiting fluorescence artifacts.
Two compounds that consistently activated IDE—dubbed Ia1
and Ia2 (IDE activators 1 and 2; LDN-1487 and LDN-1844,
respectively)—emerged from the screening campaign (Fig. 2A,B).
Ia1 activated the hydrolysis of SP1 and FRET1 by up to ,200%
and ,500%, respectively, in a dose-dependent manner, with
maximal activation occurring at 200 mM (Fig. 2A). Ia2 also
activated both substrates, albeit to a lesser extent: maximal
activation by Ia2 was determined to be ,110% and ,60% at
concentrations of 50 mM and 6.25 mM, for SP1 and FRET1,
respectively.
A small number of compounds structurally related to Ia2 were
either present in the compound library or available commercially,
allowing the structure-activity relationship to be investigated.
These compounds all contained 4-[5-furan-2-yl)-1H-pyrazol-3-
yl]piperidine, with different substitutions at the piperidine nitrogen
Activators of IDE
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5274functionality (Fig. 2A,B). When tested at 10 mM, the percent
activation produced by different substitutions followed the series:
-H,-CH2NC<(4-methylphenyl)sulfonyl#-CONH-3-chlorophenyl,
with maximal activation produced by Ia2 itself (Fig. S2).
Although Ia1 and Ia2 and its variants show no obvious
structural (Fig. S3) or chemical (Table S1) relationship to ATP
or other nucleotide polyphosphates, their similar size and common
ability to activate IDE suggested that they may exert their effects
Figure 1. Assay development and rationale for parallel high-throughput IDE activator screening campaigns incorporating ATP. A,
ATP inhibits IDE-mediated degradation of Ab at physiological concentrations. B, Paradoxical ATP-mediated activation of the IDE-mediated hydrolysis
of a fluorogenic peptide substrate. C, D, Dose-response of ATP on the hydrolysis of two structurally similar fluorogenic peptide substrates, SP1 (C) and
FRET1 (D). Note the different degrees of maximal activation obtained for SP1 vs. FRET1. See Fig. S1 for a comparison of the structures of SP1 and
FRET1. E, A subset of primary screening data showing percent activity in the presence vs. the absence of ATP (1 mM). Rounded rectangles show
different categories of hits that can theoretically be identified using this approach, including (i) compounds that mimic ATP, (ii) compounds that
activate IDE independently of ATP, (iii) compounds that act synergistically with ATP, and (iv) compounds that disrupt the activation effect induced by
ATP. Data are mean6SEM for 4 to 5 independent experiments each comprising 3 to 4 replicates and normalized to control wells containing no ATP.
For panels A, C and D, all data for concentrations of ATP above 10 mM are significantly different from the no-ATP controls (P,0.05).
doi:10.1371/journal.pone.0005274.g001
Figure 2. Small-molecule activators of IDE discovered through compound screening. A,B, Structures of Ia1 (A) and Ia2 (B) and dose-
dependent effects on the IDE-mediated hydrolysis of SP1 and FRET1. Data are mean6SEM for 4 to 5 independent experiments normalized to control
wells containing no ATP. Data for all doses showing $30% activation are statistically different from DMSO controls (P,0.05).
doi:10.1371/journal.pone.0005274.g002
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this hypothesis, we tested the ability of Ia1 and Ia2 to interfere
with the binding of ATP, as determined from the labeling of
recombinant IDE with a biotinylated photoaffinity ATP analogue,
8-azidoadenosine 59-triphosphate 29,39-biotin-LC-hydrazone (az-
ido-ATP-biotin). Under conditions that produced substantial
photocrosslinking of IDE, Ia1 and Ia2 both interfered with
azido-ATP-biotin labeling in a dose-dependent manner, an effect
that was also produced by excess unlabeled ATP, as expected
(Fig. 3A). To investigate the interaction of Ia1 and Ia2 with one
another, we tested and confirmed the ability of Ia2 to interfere
with the more pronounced activation effect produced by Ia1
(Fig. 3B). Together, these results support the idea that Ia1 and Ia2
both exert their effects through interaction with a common
domain within IDE that also binds to ATP.
To further explore the functional interrelationship among ATP
and the identified IDE-activating compounds, we determined the
degree of activation produced by different doses of Ia1 and Ia2 in
the absence or presence of a partially activating concentration of
ATP (0.1 mM). Based on the preceding analysis we expected that
the identified compounds would, depending on their relative
binding affinities and activating potential, either block the
activating effect of ATP or have little or no additional activating
effect. Instead, when SP1 was used as a substrate, a pronounced
synergistic activation effect was observed between ATP and both
Ia1 and Ia2 (Fig. 4), increasing IDE activity to a degree not
achieved with ATP alone (e.g.,t o,1000% for Ia1 and ATP; c.f.
Fig. 1C). A similar interaction between ATP and the activating
compounds was observed for FRET1 (not shown).
We then explored the effects of Ia1 and Ia2 on the degradation
of Ab by IDE. To the extent that the IDE-activating compounds
mimic the actions of ATP, they were predicted to exert no effect or
even to inhibit IDE-mediated Ab degradation. Alternatively,
however, they might prove capable of relieving the inhibitory
effect of ATP on Ab degradation (see Fig. 1A), thereby activating
the protease. To explore these possibilities, we tested the effects of
Ia1 and Ia2 on IDE-mediated Ab degradation in the absence or
presence of a partially inhibitory concentration of ATP (5 mM).
With the exception of very high doses of Ia1 or Ia2, which elicited
partial inhibition, we observed no significant effect of Ia1 and Ia2
on Ab degradation in the presence or absence of ATP (Fig. 5A,B).
Although Ia1 or Ia2 failed to activate the degradation of Ab by
itself, we reasoned that activation may yet occur when Ab is
present in a more complex mixture also containing shorter
substrates whose hydrolysis can be affected by the activating
compounds. To test this idea, we monitored the degradation of Ab
mixed together with FRET1. Under these conditions, Ia1 and Ia2
were both found to produce significant activation of IDE-mediated
Ab degradation (Fig. 5C,D). Similar effects were observed in the
presence of SP1 (not shown). It is notable that the degree of
activation of Ab degradation induced by Ia1 and Ia2 under these
conditions exceeded that achieved with FRET1 or SP1 alone (c.f.
Figs. 2 and 5C,D).
Discussion
In the present study we conducted a high-throughput
compound screening campaign optimized to discover compounds
that interact with a putative ATP-binding domain within IDE. We
succeeded in identifying two compounds, Ia1 and Ia2, that
significantly stimulate IDE proteolytic activity, which were
characterized extensively in vitro. To our knowledge, Ia1 and Ia2
are the first drug-like compounds (i.e., conforming to Lipinski’s
rules [32]) shown to activate this important protease.
Despite the lack of structural or chemical similarities to ATP or
other nucleotide polyphosphates, Ia1 and Ia2 both exhibited
largely similar enzymologic properties as the latter molecules. Like
nucleotide polyphosphates, Ia1 and Ia2 both stimulated the
proteolysis of short peptide substrates, but failed to affect full-
length Ab when presented as the sole substrate. Significantly, both
of the IDE-activating compounds we identified were capable of
blocking the crosslinking of IDE with a photoaffinity ATP
analogue, and the activating effect of one compound, Ia1, could
be blocked by the more weakly activating compound, Ia2. Taken
together, these results suggest that ATP, Ia1 and Ia2 all interact
with a common domain within the IDE molecule.
The latter conclusion, however, is seemingly contradicted by the
fact that Ia1 and Ia2 were each found to act synergistically with
ATP, notably activating IDE to a degree not achieved with ATP,
Ia1 or Ia2 alone. One possibility is that Ia1 and Ia2 bind to a
separate, perhaps partially overlapping site, which in turn affects
ATP binding. Under this scenario, it is possible that the activating
compounds may only subtly affect the positioning of ATP, rather
than its binding per se, which could in turn influence the ability of
azido-ATP-biotin to crosslink to IDE.
Another important observation that may also help to explain
this apparent discrepancy is the finding that IDE can be activated
not only by nucleotide triphosphates, but also by inorganic
triphosphate (PPPi) alone [24,29]. Despite similar activation
effects, dissociation has been observed between the effects of
ATP and PPPi in two important respects. First, ATP, but not
PPPi, was found to slow the electrophoretic mobility of IDE under
native conditions [24]. Second, ATP, but not PPPi, was found to
Figure 3. Ia1, Ia2 and ATP interact with a common domain
within IDE. A, Ia1 and Ia2 disrupt the crosslinking of recombinant IDE
with a photoaffinity ATP analogue. DMSO concentrations were
maintained constant in all conditions; CTL=DMSO only; ATP=10mM
ATP. B, Activation of FRET1 hydrolysis by Ia1 can be competed away
with increasing doses of Ia2. Data are mean6SEM for 5 independent
experiments normalized to control wells containing DMSO only. All data
are statistically different from controls (P,0.05).
doi:10.1371/journal.pone.0005274.g003
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determined from circular dichroism experiments [24]. The latter
results indicate that PPPi, possibly by virtue of its highly polar
nature, can induce effects that are independent of the ability of the
full-length ATP molecule to bind to IDE. Thus, it seems plausible
that the synergistic effects observed between ATP and Ia1 or Ia2
could be attributable to an interaction between their binding to a
bona fide nucleotide polyphosphate-binding domain within IDE
combined with non-specific effects induced by the highly charged
triphosphate moiety within ATP.
The preceding conclusion is further supported by the fact that
multiple, distinct mechanisms have been proposed to underlie
activation of ATP by IDE. One proposed mechanism points to
effects on IDE’s quaternary structure. IDE normally exists as a
homodimer, but can also assemble into higher n-oligomers, the
formation of which inhibits IDE activity [23,29]. Accordingly, gel
filtration experiments have demonstrated that ATP suppresses
higher n-oligomer formation [29]. A second mechanism suggests
that ATP may act by influencing the transition between the
‘‘open’’ configuration of IDE and its ‘‘closed’’, inactive confor-
mation. This model is supported by the observation that ATP can
induce increases in the hydrodynamic radius of IDE as detected by
dynamic light scattering [24]. The observed synergy between ATP
and Ia1 or Ia2 might therefore be explained if either or both of the
latter mechanisms are induced by the triphosphate moiety within
ATP, but not by Ia1 or Ia2 alone.
If the aforementioned mechanisms apply only to effects induced
by the triphosphate moiety of ATP, what mechanism(s) underlies
the effects of Ia1, Ia2, and, by extension, nucleotide polypho-
sphates, when bound to the domain(s) with which they interact?
Though purely speculative, an attractive possibility is that these
molecules all bind to one or more sites located within the internal
chamber of IDE. Such binding would be predicted to decrease the
volume accessible to substrate, thereby reducing the degrees of
freedom available for its positioning and so increasing the
probability that it will adopt a proteolysis-competent conformation
(see [25]). This model might also help to explain why ATP (and
Ia1 and Ia2 at high concentrations) inhibits the hydrolysis of larger
substrates such as insulin or Ab: by virtue of their larger size, these
substrates might be incapable of occupying the internal chamber
together with ATP or the activating compounds we identified.
In terms of potential binding domains within IDE, it is notable
that an exosite has been identified within IDE’s internal chamber
[23–25]. Crystal structures of IDE show that this domain is located
at the opposite side of the internal chamber as the active site, is
involved in the binding of larger substrates, and shows a
propensity to bind smaller peptides, as well [23–25]. While it
remains plausible that Ia1, Ia2 and ATP exert their action through
binding to this domain, we note that the screening campaign
included 4096 tetrapeptides, none of which exhibited activation
effects comparable to Ia1 or Ia2, either in the presence or absence
of ATP.
Figure 4. Synergistic effects of ATP and Ia1 or Ia2. A,B, Activating effects of Ia1 (A) and Ia2 (B) on IDE-mediated hydrolysis of SP1 when tested
in the absence or presence of ATP (0.1 mM). Data have been normalized to controls containing DMSO only or DMSO plus ATP, respectively. C,D,
Pronounced synergy between ATP and Ia1 (50 mM; C) and Ia2 (10 mM; D). In this case, data are presented as raw activation values, all normalized to
DMSO-only controls lacking ATP. Dashed columns show the predicted magnitude of activation if the effects of ATP and Ia1 or Ia2 were simply
additive. Data are mean6SEM for 4 independent experiments. For panels A and B, data showing $30% activation are statistically different from
corresponding controls (P,0.05). For panels C and D, data are statistically different for all comparisons (P,0.01).
doi:10.1371/journal.pone.0005274.g004
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the observation Ia1 and Ia2 significantly activated the degradation
of Ab when presented in a mixture together with a shorter
substrate, though not when Ab was presented alone. Significantly,
the degree of activation of Ab degradation under the former
conditions was larger than observed for the shorter substrate by
itself. Mechanistically, we speculate that this phenomenon may be
related to positive intersubunit cooperativity conferred by the
homodimeric configuration of IDE. Under this scenario, the
interaction of one subunit with substrate may render the other
subunit more capable of binding substrate (or releasing products)
through allosteric effects. Such an effect might be more
pronounced for combinations of different substrates than for a
single substrate presented alone. At a more practical level, this
result contains an important lesson for future compound screening
campaigns: whereas it is commonly considered desirable to utilize
the most reductionistic arrangement possible, our results suggest
that screening with a single substrate may not be ideal in the case
of IDE. Instead, it may be preferable to screen under conditions
that contain a complex mixture of substrates, ideally mimicking as
closely as possible the substrate milieu in which therapeutic
compounds are eventually intended to act. Indeed, given IDE’s
unusual structure, mode of substrate processing and sensitivity to
endogenous cofactors [23], it may ultimately be possible to identify
compounds that operate in one physiological context but not
others (e.g., intracellular vs. extracellular).
By way of conclusion, we point out that ATP is just one of
several candidate endogenous inhibitors of IDE. Other attractive
candidates include ubiquitin [33] and long-chain fatty acids [34].
The general strategy we employed—namely, conducting parallel
screens in the presence or absence of the putative endogenous
inhibitor—appears to be ideal for reliably identifying compounds
that displace endogenous inhibitors and for rapidly distinguishing
them from compounds acting by alternative mechanisms.
Materials and Methods
Chemicals
The compound library used for screening was comprised of
commercially available compounds purchased from Peakdale
(High Peak, UK), Maybridge Plc. (Cornwall, UK), Cerep (Paris,
France), Bionet Research Ltd. (Cornwall, UK), Prestwick (Ilkirch,
France), Specs and Biospecs (CP Rijswijk, the Netherlands),
ENAMINE (Kiev, Ukraine), and ChemDiv (San Diego, CA). Ia1
and Ia2 were purchased from Bionet. SP1 was synthesized by
SynPep Corp. (Dublin, CA). FRET1 was synthesized by Margaret
Condron and David Teplow as described [28]. Azido-ATP-biotin
was purchased from ALT Bioscience (Lexington, KY). All other
chemicals and reagents were purchased from Sigma-Aldrich Co.
(St. Louis, MO).
High-throughput compound screening
Compounds were spotted robotically onto black 384-well plates
(0.4 mL/well, 50 mM final concentration) and stored at 280uC.
On the day of screening, plates were thawed, then reagents
dissolved in reaction buffer (50 mM Tris HCl, pH 7.4 supple-
Figure 5. Effects of Ia1 and Ia2 on Ab degradation. A,B, Ia1 (A) and Ia2 (B) fail to activate the degradation of Ab, in the presence or the absence
of ATP, when Ab is the sole substrate; Instead, partial inhibition is seen at higher concentrations. Data are mean6SEM for 4 independent experiment;
*P,0.05. C,D, Ia1 and Ia2 strongly activate Ab degradation when presented together with a short substrate (FRET1; 10 mM). C, Representative time-
course of Ab activation by Ia1 and Ia2. D, Results of 4 independent experiments showing results normalized to DMSO-only controls. Data are
mean6SEM and are statistically different for all comparisons (P,0.01).
doi:10.1371/journal.pone.0005274.g005
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FX Laboratory Automation Workstation (Beckman-Coulter)
under either of two conditions. For experiments carried out in
the absence of ATP, recombinant IDE (30 mL/well, 6 nM final
concentration) was added robotically, agitated on an orbital shaker
for 1 min to facilitate mixing, then allowed to equilibrate with
compounds for 1 h at room temperature. The reaction was then
initiated by addition of SP1 (6 mM final concentration; 10 mL/
well), agitated for 1 min, then terminated 4 h later by addition of
stop buffer (0.1 M NaOAc, pH 4.0; 10 mL/well). For experiments
carried out in the presence of ATP, the recombinant IDE solution
was supplemented with ATP (1 mM final concentration) and the
reaction time was adjusted to 1.5 h. Controls added to each assay
plate included wells lacking IDE (0% activity), recombinant IDE
supplemented with DMSO (0.4 mL/well), recombinant IDE
supplemented with the competitive inhibitor, insulin (10 mM final
concentration), and excess IDE (20 nM final concentration; 100%
activity. Activity was assessed by quantification of fluorescence
intensity (lex 330 nm, lem 450 nm) using an Analyst HT
multilabel plate reader (Molecular Devices) equipped with
integrated stackers. To minimize the influence of the intrinsic
fluorescence of compounds, fluorescence was quantified immedi-
ately after termination of the reaction and subtracted from the
fluorescence measurement determined after addition of substrate.
Raw fluorescent data were converted to % activity by normali-
zation to intra-plate controls. For replication experiments,
compounds were cherry-picked from thawed DMSO stocks,
spotted manually onto assay plates and processed as above.
Dose-response determinations
For compounds showing reproducible activation, DMSO stocks
were cherry-picked, diluted in DMSO, spotted manually onto
assay plates, then assayed as above, albeit using manual solution
transfers. For these experiments, the reaction was monitored
continuously by determining fluorescence intensity (lex 330 nm,
lem 420 nm) at 2-min intervals using a Gemini XL multilabel
plate reader (Molecular Devices).
Enzymologic studies
Compounds selected for further in vitro characterization were
purchased from commercial vendors as lyophilized stocks,
resuspended in DMSO, and stored in aliquots at 280uC. Assays
incorporating fluorogenic substrates SP1 and FRET1 (5 mM) were
conducted essentially as above using a SpectraMax M5 multilabel
plate reader (Molecular Devices). Degradation of Ab (50 nM) was
quantified as described [35].
Photoaffinity labeling
Photocrosslinking with azido-ATP-biotin was conducted ac-
cording to manufacturer’s recommendations (ALT Bioscience).
Briefly, the ATP analogue dissolved in MeOH was added to
0.2 mL tubes (5 nmol/tube), and MeOH was removed by
lyophilization. The ATP analogue was dissolved in a solution
containing 20 nM recombinant IDE (10 mM HEPES pH 7.4),
then reactions were exposed to UV radiation (254 nm, 5 mW/
cm
2) for 2 min using a hand-held lamp and terminated by addition
of dithiothreitol (to 10 mM final concentration). The terminated
reactions were processed by conventional SDS-PAGE under
denaturing and reducing conditions and transferred to nitrocellu-
lose membranes as described [9]. Membranes were blocked in 5%
non-fat milk in Tris-buffered saline supplemented with 0.2%
Tween-20 (TBS-T), incubated for 1 h with anti-biotin monoclonal
antibody, BN-34 (1:1000; Sigma), washed in TBS-T, incubated
with a peroxidase-conjugated anti-mouse IgG secondary antibody
(1:5000, Vector Labs), washed, then detected by enhanced
chemoluminescence.
Supporting Information
Figure S1 Chemical structures of SP1 and FRET1.
Found at: doi:10.1371/journal.pone.0005274.s001 (0.07 MB TIF)
Figure S2 Structure-activity relationships for variants of Ia2. A,
Domain within Ia2 that is common to all variants. B, Activity (left)
of Ia2 variants containing different substitutions (right).
Found at: doi:10.1371/journal.pone.0005274.s002 (0.09 MB TIF)
Figure S3 Chemical structures of Ia1 (A), Ia2 (B) and ATP (C).
Found at: doi:10.1371/journal.pone.0005274.s003 (0.09 MB TIF)
Table S1 Comparison of selected chemical properties of Ia1, Ia2
and ATP.
Found at: doi:10.1371/journal.pone.0005274.s004 (0.03 MB
DOC)
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